共 137 条
[1]
Block GA(2000)Prevalence and clinical consequences of elevated Ca × P product in hemodialysis patients Clin Nephrol 54 318-324
[2]
Goodman WG(2001)Recent developments in the management of secondary hyperparathyroidism Kidney Int 59 1187-1201
[3]
Delmez JA(1989)Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium J Clin Invest 83 1349-1355
[4]
Tindira C(2011)Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism Kidney Int 79 112-119
[5]
Grooms P(2004)Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis N Engl J Med 350 1516-1525
[6]
Dusso A(2005)Treatment of secondary hyperparathyroidism of dialysis patients with calcimimetics as a valuable addition to established therapeutic means Pediatr Nephrol 20 399-403
[7]
Windus DW(2005)Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study J Am Soc Nephrol 16 800-807
[8]
Slatopolsky E(2005)Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl Nephrol Dial Transplant 20 2186-2193
[9]
Wesseling-Perry K(1998)Calcimimetics with potent and selective activity on the parathyroid calcium receptor Proc Natl Acad Sci USA 95 4040-4045
[10]
Pereira RC(1993)Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid Nature 366 575-580